We next tested the interaction of CK1α inhibition with Duvelisib, a PI3Kγ/δ inhibitor approved for the treatment of Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL). The gene discussed is CSNK1A1; the disease is B-cell chronic lymphocytic leukemia.